AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Hyper IgM Syndrome

Recent research efforts aimed at curing Hyper IgM Syndrome.

Last updated

Hyper IgM Syndrome

Overview

Hyper IgM syndrome is a group of rare inherited immune disorders in which the body has trouble making several important antibody types—especially IgG and IgA—even though IgM may be normal or high. The best-known form, X-linked Hyper IgM syndrome (HIGM1), is caused by harmful variants in CD40LG, which disrupt communication between activated T cells and B cells. It usually affects boys and often begins in infancy or early childhood with recurrent respiratory infections, opportunistic infections such as Pneumocystis jirovecii, chronic diarrhea, poor growth, low neutrophil counts, and sometimes liver disease or cancer risk. In CD40 ligand deficiency, more than half of affected males develop symptoms by age one and more than 90% by age four; the reported median survival from diagnosis is 25 years, although outcomes vary substantially with modern prevention and treatment. CD40 Ligand Deficiency

Current care aims to prevent infections and organ damage through immunoglobulin replacement, antimicrobial treatment and prophylaxis, monitoring for liver and gastrointestinal disease, and management of complications such as neutropenia. For CD40 ligand deficiency, allogeneic hematopoietic stem cell transplantation (HSCT)—replacement of blood-forming stem cells using cells from a donor—is the only established curative treatment, ideally performed before major organ dysfunction develops. CD40 Ligand Deficiency

Scope of Recent Research (2020–present)

Research activity has accelerated most clearly for X-linked CD40LG deficiency, which accounts for most Hyper IgM syndrome and is well suited to gene correction because the disease arises from a single gene defect in immune cells. The dominant questions are whether a patient’s own blood-forming stem cells can be edited safely enough to provide lifelong immune reconstitution, whether edited T cells can provide faster temporary protection, and how to preserve normal, tightly controlled CD40L expression. As of August 8, 2026, the field has moved from compelling patient-cell and animal studies to an initial single-patient clinical study, but it remains far from a broadly validated, routinely available gene-based cure. Modeling gene editing for Hyper-IgM First-in-human base-edit therapy

Major Breakthroughs and Emerging Therapies

The most consequential advance is the first reported use of autologous base-edited stem cells and T cells in a person with CD40L deficiency. Base editing changes a target DNA letter without making the double-strand DNA break used in conventional CRISPR cutting. In this case, NIH investigators used an adenine base editor to correct the patient-specific CD40LG Q220X mutation in both blood-forming stem/progenitor cells and T cells. The edited T cells were intended as a rapid “bridge” while edited stem cells established durable production of new immune cells. At one and two months after stem-cell infusion, the investigators reported more than 90% corrected alleles in myeloid cells, increasing correction in natural-killer, B, and T cells, and the first detection of class-switched IgG-positive B cells; these observations are encouraging but are extremely early results from one patient reported in a meeting abstract rather than a completed peer-reviewed clinical trial. First-in-human base-edit therapy

A parallel strategy uses CRISPR-Cas9 with homology-directed repair (HDR), the cell’s template-guided DNA-repair pathway, to insert a functional CD40LG sequence into its natural genomic location in hematopoietic stem and progenitor cells (HSPCs). This placement is important because CD40L must be switched on at the right time and level, rather than expressed continuously. In a 2024 preclinical study, adding the DNA-PK inhibitor AZD7648 increased targeted HDR correction at CD40LG to about 60% in mobilized human CD34-positive cells and improved the representation of corrected long-term engrafting cells in primary and secondary mouse xenografts. DNA-PK inhibition for CRISPR correction

Edited T-cell products may offer a second, potentially less intensive route to restoring CD40L function, although they would not by themselves replace the entire blood and immune system. A 2023 study developed a scalable, good-manufacturing-practice-compatible process using Cas9 and an integrase-defective lentiviral donor template to insert a broadly applicable corrective sequence into CD4-positive T cells. Edited cells from healthy donors and patients retained central and stem-like memory characteristics, showed physiologically regulated CD40LG expression and function, and persisted in mouse xenograft experiments. GMP-compatible T-cell correction

Researchers are also improving safety and breadth. A 2023 genome-integrity study found that some harmful on-target deletions were selected against during culture and could be reduced by enriching the corrected cells, but it also detected occasional trapping of donor-vector copies at the editing site—an outcome that did not prevent function in the tested cells but requires careful product-specific monitoring. Meanwhile, UCLA received a 2026 seed grant to develop prime-editing approaches for nine patient-specific CD40LG mutations. Prime editing is designed to make precise sequence changes without double-strand DNA breaks or a conventional viral DNA donor, but this Hyper IgM work remains preclinical. Genome-integrity assessment in edited T cells Hyper IgM Foundation research grants

Clinical Trials and Experimental Approaches

The leading clinical effort is the NIAID-sponsored, single-participant Phase 1/2 study, NCT06959771, conducted at the NIH Clinical Center in Bethesda, Maryland. The study began on July 16, 2025, and is designed for one adult male with the CD40LG Q220X variant. It tests a single infusion of autologous base-edited HSPCs, supported by base-edited T cells, after conditioning that includes alemtuzumab and busulfan; planned outcome measures include CD40L expression, IgG production, vaccine responses, lineage-specific correction, and whole-exome sequencing at 24 months. The registry was last verified on March 23, 2026, and listed the study as recruiting with estimated primary completion in October 2027. NCT06959771 trial record

The May 2026 report from this study described a clinically important challenge: liver tests worsened after alemtuzumab and recurrent Cryptosporidium became detectable, so the team paused conditioning and infused the edited T-cell product first. The reported improvement in liver tests then allowed busulfan conditioning and edited-HSPC infusion. This adaptive dual-cell strategy is innovative, but durable antibody independence, infection control, long-term engraftment, and delayed genotoxicity remain unproven. First-in-human base-edit therapy

HSCT research also continues to improve the available cure. A 2022 study of four patients receiving transplants from asymptomatic female CD40LG carriers reported engraftment, good immune reconstitution, no graft-versus-host disease or opportunistic infections during one to five years of follow-up, and immunoglobulin independence in three patients. A 2026 case report further described sustained immune recovery 7.5 years after transplant from a carrier mother, despite approximately 32% CD40L expression, suggesting that carrier relatives can sometimes be viable donors after careful evaluation. Carrier-donor HSCT study Carrier-donor transplant case report

Methodologies and Scientific Approaches

Hyper IgM cure research combines patient-derived CD4-positive T cells and CD34-positive HSPCs with disease-model mice and human-cell xenografts. Investigators measure correction at the DNA level, CD40L expression after T-cell activation, class-switched memory B cells, immunoglobulin production, immune-cell diversity, resistance to opportunistic infection, and long-term multilineage engraftment. Delivery platforms include electroporated Cas9 or base-editor messenger RNA/protein complexes, adeno-associated virus serotype 6 donor templates for HDR, and integrase-defective lentiviral vectors for T-cell correction. Modeling gene editing for Hyper-IgM DNA-PK inhibition for CRISPR correction GMP-compatible T-cell correction

Leading Institutions and Funding

The clinical base-editing program is led by the National Institute of Allergy and Infectious Diseases and NIH Clinical Center, with collaborators from the Frederick National Laboratory for Cancer Research, NIH’s Center for Cellular Engineering, UT Southwestern, CellScript/Wisconsin Institute for Immune and Cell Therapy, and Massachusetts General Hospital. Seattle Children’s Research Institute, the University of Washington, and CSL Behring contributed to the HDR-HSPC work, while the San Raffaele Telethon Institute for Gene Therapy has advanced T-cell editing and genome-integrity studies. First-in-human base-edit therapy DNA-PK inhibition for CRISPR correction

Patient-led philanthropy has played an unusually direct role in this small field. The Hyper IgM Foundation awarded $100,000 in 2023 to support genome-integrity characterization of edited CD4-positive T cells at San Raffaele, $75,000 in 2025 to Duke University and NIAID collaborators for in vivo editing research, and $100,000 in 2026 to UCLA for preclinical prime-editing development; it also awarded $25,000 in 2026 to Baylor College of Medicine for a functional atlas of CD40 and CD40LG variants. Hyper IgM Foundation research grants

Strengths, Limitations, and Challenges

The scientific rationale is strong: restoring CD40L in a patient’s own immune system could avoid donor matching, graft rejection, and graft-versus-host disease while preserving native control of a gene whose overexpression can be harmful. The first treated patient provides an important proof of clinical feasibility, and the observed early multilineage correction and emergence of class-switched B cells are biologically meaningful. HSCT also remains an effective real-world cure when a suitable donor is available, including in carefully selected carrier-donor settings. First-in-human base-edit therapy Carrier-donor HSCT study

The limitations are substantial. The first gene-editing result involves one 37-year-old participant with only one to two months of reported follow-up, and treatment still required chemotherapy-based conditioning, which can be particularly hazardous in people with pre-existing liver disease. Conventional CRISPR-HDR editing may cause unintended edits, large on-target DNA changes, or impaired long-term stem-cell fitness; base and prime editing may reduce double-strand-break risks but introduce their own off-target and delivery concerns. Finally, CD40LG-directed therapies will not automatically cure other Hyper IgM syndromes caused by defects such as CD40, AICDA, or UNG; for example, a 2023 review identified only 40 reported patients with CD40 deficiency, underscoring how limited the evidence base is for rarer genetic subtypes. Genome-integrity assessment in edited T cells Clinical features of CD40 deficiency

Outlook and Future Directions

Hyper IgM syndrome is closer to a gene-based cure than it was in 2020, but not yet close to a standard gene therapy. The key milestones to watch are durable follow-up from NCT06959771 through and beyond its estimated October 2027 completion, sustained infection-free and immunoglobulin-independent immune function, confirmation that corrected stem cells maintain safe long-term blood production, and replication in additional patients with different CD40LG variants. If those milestones are met, next-generation approaches such as prime editing and less-toxic conditioning could broaden access; until then, early expert care, infection prevention, and appropriately timed HSCT remain central to saving lives. NCT06959771 trial record Hyper IgM Foundation research grants

References

Don't see your disease? Request a report